Study of Maternal Melatonin Supplementation to Protect Brain Development in Severe Early Preterm Fetal Growth Restriction
Led by Monash University · Updated on 2025-06-06
336
Participants Needed
12
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Fetal growth restriction FGR affects many pregnancies and is linked to serious risks including stillbirth, preterm birth, and long-term developmental challenges such as cerebral palsy. This trial evaluates whether giving pregnant women melatonin can protect the fetal brain and improve neurodevelopmental outcomes in babies affected by early-onset severe FGR. The study is a triple-blind, randomized, placebo-controlled trial aiming to address the lack of treatments to enhance fetal wellbeing before birth.
Participants will receive either melatonin tablets 10 mg three times daily for a total of 30 mg per day or matching placebo tablets three times a day. The trial includes pregnancies diagnosed with severe FGR between 23 and 31 weeks gestation. Treatment continues until birth. The study is conducted across multiple centers, with participant groups randomized based on gestational age to allow sub-analysis of early and late onset FGR.
Participants will be monitored throughout pregnancy with assessments of fetal growth and placental blood flow. After birth, childrens neurodevelopment will be evaluated at 2 years of age using the Bayley-IV Cognitive scale. Researchers will also track side effects, maternal organ function, and fetal wellbeing until birth. The total participation duration varies depending on gestational age at enrollment and follow-up visits extend to 2-3 years of the childs life for outcome measurement.
CONDITIONS
Brief Title
Antenatal Melatonin Supplementation for Neuroprotection in Fetal Growth Restriction
Research Team
K
Kirsten Palmer, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
National Health and Medical Research Council, Australia
Collaborating Sponsor
Who Can Participate
Age: 18Years +
FEMALE
Healthy Volunteers
Eligibility Criteria
You may qualify if you...
Singleton pregnancy
Severe fetal growth restriction defined by abdominal circumference ≤3rd centile for gestational age or <10th centile with abnormal fetoplacental Doppler
Confirmed gestational age between 23 weeks 0 days and 31 weeks 6 days
Age 18 years or older
Understand English
You will not qualify if you...
Known chromosomal or major structural fetal anomaly or non-placental cause of fetal growth restriction
Pregnancies requiring immediate delivery due to urgent fetal condition
Participation in another clinical trial with pharmaceutical or nutritional supplements affecting oxidative stress
Currently prescribed Fluvoxamine
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 screening and enrollment visit
Treatment
Duration - Up to 17 weeks or until birth
Participants receive melatonin or placebo tablets three times a day during pregnancy until birth to evaluate neuroprotective effects in fetal growth restriction.
Regular visits during treatment as determined by clinical care
Follow-up
Duration - 24 to 36 months corrected age
Participants and their children are followed up to assess neurodevelopmental outcomes at 2 years of age among survivors.
1 to 2 visits depending on neurodevelopmental assessment schedule
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Study of Maternal Melatonin Supplementation to Protect Brain Development in Severe Early Preterm Fetal Growth Restriction
Study of Lactoferrin and DHA Supplements in Pregnant Women with Fetal Growth Restriction
Impact on Babys Brain Development and Birth Outcomes
Study of a Structured Ultrasound Program for Monitoring Fetal Growth and Reducing Stillbirth Risks in Pregnant Women at Oxford University Hospitals
Study to Identify Preventable Factors Linked to Early Stillbirth Between 20 and 28 Weeks of Pregnancy
Study of Periodontal Treatment During Pregnancy to Reduce Risks of Preterm Birth, Low Birthweight, and Pregnancy Complications
PROTECT-Africa Validating Biomarker Tests to Improve Preeclampsia Care in African Pregnancies
International Study on Selective Fetal Growth Restriction in Monochorionic Diamniotic Twin Pregnancies
Improving Diagnosis, Outcome Prediction, and Parental Support
Comparing Computerized Short-Term Variation Analysis and Visual Cardiotocography to Guide Delivery Timing in Severe Early-Onset Fetal Growth Restriction
Evaluating the Periviable GOALS Decision Support Tool for Shared Decision Making in Periviable Pregnancy Care
Testing New Non-Stick Sensors to Monitor Babys Heartbeat and Movements in Late Pregnancy